Search Results
Jul 15, 2026, 05:11 ET Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment
Endpoints for Decentralized Alzheimer's Trials: Experience from the CNS-101 Study (NeuLogiq®),' was presented by Dr. James Rowe, Professor of Cognitive Neurology at the University of Cambridge and Principal Investigator on CNS-101. This study confirmed NeuLogiq Platform cognitive and EEG assessments
More news about: Cumulus Neuroscience
Jul 15, 2026, 05:00 ET Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment
Decentralized Alzheimer's Trials: Experience from the CNS-101 Study (NeuLogiq®),' was presented by Dr. James Rowe, Professor of Cognitive Neurology at the University of Cambridge and Principal Investigator on CNS-101. This study confirmed NeuLogiq Platform cognitive and EEG assessments
More news about: Cumulus Neuroscience
Jul 14, 2026, 21:09 ET GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million
with BeOne Medicines' PD-1 antibody, tislelizumab. CX-4945 is being investigated across several oncology indications, including cholangiocarcinoma, CNS tumors and pediatric cancers. In addition, preclinical studies are evaluating both compounds as potential combination partners for RAS-targeted therapies,
More news about: Senhwa Biosciences, Inc
Jul 14, 2026, 08:00 ET Cottage Health Expands Partnership with hellocare.ai Following Successful Pilot to Deploy AI Assisted Virtual Care and Patient Safety Platform Enterprise Wide
the overall patient experience."Patient safety and exceptional care remain at the center of everything we do," said Laura Canfield, DNP, RN, CNS, Vice President, Patient Care Services and Chief Nursing Officer at Cottage Health. "The ability to proactively identify patients at risk for falls or
More news about: hellocare
Jul 13, 2026, 06:00 ET NeuroTherapia to Present Phase 2a Alzheimer's Disease Clinical Data at the AAIC 2026 Conference in London, UK
sclerosis, and other CNS disorders. There is an emerging consensus that neuroinflammation plays a significant role in CNS disease. NeuroTherapia is a leader in developing novel therapeutics that modulate microglial activity, impacting the expression of proteins that drive inflammation in the CNS, thereby improving
More news about: NeuroTherapia, Inc.
Jul 13, 2026, 04:00 ET Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference® (AAIC®) 2026
t-tau increased after etalanetug administration in both individuals with DIAD and healthy adults. This change is considered to be attributable to non-CNS tau species derived from peripheral tissues being stabilized by binding to etalanetug in plasma, thereby inhibiting their degradation.Plasma
More news about: Eisai Inc.
Jul 12, 2026, 20:30 ET Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
content:https://www.prnewswire.com/news-releases/deepening-collaboration-in-ai-powered-rd-acceleration-insilico-medicine-and-cms-announce-additional-collaborations-in-cns-diseases-302823160.htmlSOURCE
More news about: Insilico Medicine
Jul 09, 2026, 17:00 ET Biohaven Announces Scientific Leadership Transitions
our diverse portfolio of drug candidates. Together, these two executive transitions will position us to sustain our discovery momentum and pursue new CNS therapies grounded in human biology and translational innovation."Dr. Bruce Car added, "The timing of my retirement and transition reflects my
More news about: Biohaven Ltd.
Jul 09, 2026, 16:23 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for June 2026
NEW YORK, July 9, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $100.1 billion as of June 30, 2026, an increase of $644 million from assets under management of
More news about: Cohen & Steers, Inc.
Jul 09, 2026, 11:50 ET Connected Nation launches Kentucky-based attempt to set a GUINNESS WORLD RECORDS™ title and achieve the commonwealth's first 'Record of Good' designation
expand the initiative's reachParticipating online to support and learn valuable digital skillsThis initiative builds on CN's 25-year mission — rooted in Kentucky — to expand access to broadband and ensure people have the knowledge and tools to use it effectively. To learn
More news about: Connected Nation
Jul 09, 2026, 11:18 ET The Jackson Laboratory, with the Broad Institute and Partners, Selected for ARPA-H THRIVE Award to Advance Gene Editing Platform for Pediatric Epilepsies and Rare CNS Diseases
Children with these rare CNS conditions often experience severe neurologic impairment and high mortality before the age of 5.The conventional drug development model is poorly suited to rare and ultra-rare diseases that may affect only a small number of people. For rare CNS diseases, the challenge
More news about: The Jackson Laboratory
Jul 09, 2026, 08:05 ET FDA Approves ENNUMO™ (pegfilgrastim-pccg), Accord BioPharma's Second Pegfilgrastim Biosimilar to NEULASTA® (pegfilgrastim)
Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and central nervous system (CNS) therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved ENNUMO™ (pegfilgrastim-pccg), a biosimilar to NEULASTA® (pegfilgrastim).
More news about: Accord BioPharma
Jul 09, 2026, 08:00 ET Apertura Gene Therapy Announces Cooperative Research and Development Agreement with Institutes of the NIH to Test Investigational Gene Therapy for Niemann-Pick Disease Type C1
manufacturing by contract development and manufacturing organizations (CDMOs). TfR1 CapX is a proprietary, second-generation capsid that demonstrates superior CNS delivery compared to Apertura's first-generation capsid, BI-hTFR1. Research on the first-generation BI-hTFR1 capsid was published in
More news about: Apertura Gene Therapy
Jul 09, 2026, 05:30 ET Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty
formulation development, Foresee's proprietary SIF technology platform is now expanding into the central nervous system (CNS) field, which represents a potential multi-billion-dollar market. Two CNS-targeted long-acting injectable (LAI) candidates, FP-018 (Cariprazine LAI) and FP-016 (VMAT2 LAI), are expected
More news about: Foresee Pharmaceuticals Co., Ltd.
Jul 08, 2026, 16:28 ET Cohen & Steers, Inc. to Release Second Quarter 2026 Results on July 16, 2026
NEW YORK, July 8, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release second quarter 2026 results after the market closes on Thursday, July 16, 2026. The earnings release and accompanying
More news about: Cohen & Steers, Inc.
Jul 08, 2026, 10:31 ET Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight
NBI-1065890, currently in Phase II clinical trials, is the most advanced emerging asset. Compared with many other central nervous system (CNS) disorders, the tardive dyskinesia pipeline demonstrates a relatively modest level of late-stage innovation, indicating considerable opportunities for
More news about: DelveInsight Business Research, LLP
Jul 08, 2026, 09:54 ET /C O R R E C T I O N -- Corero Network Security/
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service ("DDoS") protection specialists and champion of adaptive, real-time service availability, today announced
More news about: Corero Network Security
Jul 07, 2026, 08:00 ET Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease
clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland, and Hamilton, Bermuda. Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients
More news about: Saol Therapeutics
Jul 07, 2026, 08:00 ET Connected Nation attempts a GUINNESS WORLD RECORDS™ title to expand digital skills globally
RECORDSTM "Record of Good," a designation recognizing achievements that make a positive social impact. This initiative builds on CN's 25-year mission to expand access to broadband and ensure people have the skills to use it effectively.CN is inviting:Partners
More news about: Connected Nation
Jul 06, 2026, 08:00 ET Cumulus Neuroscience and Muse by Interaxon Bring Validated At-Home Sleep EEG to CNS Clinical Trials
with the low patient burden and repeatability required for longitudinal CNS studies — alongside NeuLogiq core measures of cognition, wake EEG, mood and speech."Objective, reliable longitudinal data are needed to advance CNS clinical development programs, which have relied on subjective measures
More news about: Cumulus Neuroscience
Jul 01, 2026, 20:05 ET Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases
BBB-crossing technology capable of enabling the delivery of a diverse range of therapeutic modalities into the central nervous system (CNS) and unlocking new opportunities in CNS drug development and technology licensing. As part of the collaboration, Lonza's protein development expertise, world-leading GS
More news about: Nona Biosciences
Jul 01, 2026, 10:31 ET High-Grade Glioma Market Witnesses Strong Momentum During the Forecast Period (2026-2036) with Increasing Clinical Activity and Drug Development | DelveInsight
Vigeo Therapeutics, Eli Lilly, Incyte Corporation, Kazia Therapeutics, Biomimetix, Medicenna Therapeutics, Immunomic Therapeutics, MimiVax, Oblato, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Imvax, BeiGene, Enterome, VBI Vaccines, Genenta Science, TME Pharma, Inovio Pharmaceuticals,
More news about: DelveInsight Business Research, LLP
Jun 30, 2026, 10:43 ET Long-Acting Drugs Market to Reach US$ 13.3 Billion by 2033 Expands Amid Advances in Sustained Drug Delivery and Chronic Disease Management - Persistence Market Research
advanced formulations that enhance bioavailability, extend therapeutic action, and minimize side effects. In 2025, investments in long-acting oncology and CNS therapies accelerated as healthcare systems prioritized improved patient outcomes and lower treatment costs.Get a Free Sample:
More news about: Persistence Market Research Pvt. Ltd.
Jun 30, 2026, 10:00 ET Headlands Research Expands California Presence with Acquisition of Clinical Trials Research
diverse patient populations, and centralized operational support. Headlands conducts clinical trials across a broad range of therapeutic areas, including CNS, vaccines, metabolic diseases, obesity, respiratory disease, cardiometabolic disorders, and more.
More news about: Headlands Research
Jun 30, 2026, 09:00 ET Cumulus Neuroscience Announces Publication in Frontiers in Digital Health Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home Cognitive and EEG Assessment in People Living with Mild Alzheimer's Disease Dementia
Final results from the CNS-101 study, published in Frontiers in Digital Health, show that the NeuLogiq Platform can be used successfully over a full year by patients living with mild Alzheimer's disease dementia. Patients in the study completed 99.7% of initiated sessions
More news about: Cumulus Neuroscience